Prenatal treatment of congenital adrenal hyperplasia

Journal of Urology

Volumn 162, Issue 2, 1999, Pages 534-536

  Speiser, Phyllis W ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Adrenal hyperplasia, congenital; Hydroxylases; Prenatal care

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; HYDROXYPROGESTERONE; MINERALOCORTICOID;

ADRENAL INSUFFICIENCY; CONFERENCE PAPER; CONGENITAL ADRENAL HYPERPLASIA; FEMALE; FEMALE PSEUDOHERMAPHRODITISM; HORMONE BLOOD LEVEL; HUMAN; INFANT; MALE; PRENATAL CARE; PRENATAL DEVELOPMENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STEROID 21 MONOOXYGENASE DEFICIENCY;

EID: 0032848613     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68623-5     Document Type: Conference Paper

References (36)

1. Villee, D. B.: The development of steroidogenesis. Amer. J. Med., 53: 533, 1972.
2. Winter, J. S. D.: The adrenal cortex in the fetus and neonate. In: Adrenal Cortex. London: Butterworths, pp. 32-56, 1985.
3. Schafer, A. J. and Goodfellow, P. N.: Sex determination in humans. Bioessays, 18: 955, 1996.
4. Rey, R. and Josso, N.: Regulation of testicular anti-Mullerian hormone secretion. Eur. J. Endocr., 135: 144, 1996.
5. Teixeira, J. and Donahoe, P. K.: Molecular biology of MIS and its receptors. J. Androl., 17: 336, 1996.
6. Jost, A.: Embryonic sexual differentiation. In: Hermaphroditism, Genital Anomalies and Related Endocrine Disorders, 2nd ed. Baltimore, Maryland: Williams & Wilkins, p. 16, 1971.
7. Wilson, J. D., Griffin, J. E. and Russell, D. W.: Steroid 5α-reductase 2 deficiency. Endocr. Rev., 14: 577, 1993.
8. Quigley, C. A., De Bellis, A., Marschke, K. B., el-Awady, M. K., Wilson, E. M., French, F. S.: Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev., 16: 271, 1995.
9. Grumbach, M. M. and Ducharme, J. R.: The effects of androgens on fetal sexual development. Androgen-induced female pseudohermaphroditism. Fertil. Steril., 11: 157, 1960.
10. Pang, S., Spence, D. A. and New, M. I.: Newborn screening for congenital adrenal hyperplasia with special reference to screening in Alaska. Ann. N.Y. Acad. Sci., 458: 90, 1985.
11. Funder, J. W.: Aldosterone action. Ann. Rev. Physiol., 55: 115, 1993.
12. Whitehead, F. J., Couper, R. T., Moore, L., Bourne, A. J. and Byard, R. W.: Dehydration deaths in infants and young children. Amer. J. Forensic Med. Path., 17: 73, 1996.
13. Pang, S. Y., Wallace, M. A., Hofman, L., Thuline, H. C., Dorche, C., Lyon, I. C., Dobbins, R. H., Kling, S., Fujieda, K. and Suwa, S.: Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics, 81: 866, 1988.
14. Silva, I. N., Kater, C. E., Cunha, C. F. and Viana, M. B.: Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch. Dis. Child., 77: 214, 1997.
15. Jaaskelainen, J. and Voutilainen, R.: Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin. Endocr., 45: 707, 1996.
16. David, M. and Forest, M. G.: Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J. Ped., 105: 799, 1984.
17. Evans, M. I., Chrousos, G. P., Mann, D. W., Larsen, J. W., Jr., Green, I., McCluskey, J., Loriaux, D. L., Fletcher, J. C., Koons, G. and Overpeck, J.: Pharmacologic suppression of the fetal adrenal gland in utero. Attempted prevention of abnormal external genital masculinization in suspected congenital adrenal hyperplasia. J.A.M.A., 253: 1015, 1985.
18. Speiser, P. W., Laforgia, N., Kato, K., Pareira, J., Khan, R., Yang, S. Y., Whorwood, C., White, P. C., Elias, S., Schriock, E., Simpson, J. L., Taslimi, M., Najjar, J., May, S., Mills, G., Crawford, C. and New, M. I.: First trimester prenatal treatment and molecular genetic diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency). J. Clin. Endocr. Metab., 70: 838, 1990.
19. Mercado, A. B., Wilson, R. C., Cheng, K. C., Wei, J. Q. and New, M. I.: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J. Clin. Endocr. Metab., 80: 2014, 1995.
20. Forest, M. G., Betuel, H. and David, M.: Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr. Res., 15: 277, 1989.
21. Migeon, C. J.: Comments about the need for prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency (Editorial). J. Clin. Endocr. Metab., 70: 836, 1990.
22. Pang, S. Y., Pollack, M. S., Marshall, R. N. and Immken, L.: Prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. New Engl. J. Med., 322: 111, 1990.
23. Forest, M. G., David, M. and Morel, Y.: Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J. Steroid Biochem. Mol. Biol., 45: 75, 1993.
24. Lajic, S., Bui, T. H., Holst, M., Ritzen, M. and Wedell, A.: Prenatal diagnosis and treatment of adrenogenital syndrome prevent virilization of female fetuses. Lakartidningen, 94: 4781, 1997.
25. Kuliev, A., Jackson, L., Froster, U., Brambati, B., Simpson, J. L., Verlinsky, Y., Ginsberg, N., Smidt-Jensen, S. and Zakut, H.: Chorionic villus sampling safety. Report of World Health Organization/EURO meeting in association with the Seventh International Conference on Early Prenatal Diagnosis of Genetic Diseases, Tel-Aviv, Israel, May 21, 1994. Amer. J. Obst. Gynec., 174: 807, 1996.
26. Goldman, A. S., Sharpior, B. H. and Katsumata, M.: Human foetal palatal corticoid receptors and teratogens for cleft palate. Nature, 272: 464, 1978.
27. Koops, B. L., Morgan, L. J., Battaglia, F. C.: Neonatal mortality risk in relation to birth weight and gestational age: update. J. Ped., 101: 969, 1982.
28. Forest, M. G.: Prenatal diagnosis and treatment of congenital adrenal hyperplasia. Clin. Courier, 16: 26, 1997.
29. Couper, J. J., Hutson, J. M. and Warne, G. L.: Hydrometrocolpos following prenatal dexamethasone treatment for congenital adrenal hyperplasia (21-hydroxylase deficiency). Eur. J. Ped., 152: 9, 1993.
30. Berenbaum, S. A. and Resnick, S. M.: Early androgen effects on aggression in children and adults with congenital adrenal hyperplasia. Psychoneuroendocrinology, 22: 505, 1997.
31. Trautman, P. D., Meyer-Bahlburg, H. F., Postelnek, J. and New, M. I.: Mothers' reactions to prenatal diagnostic procedures and dexamethasone treatment of congenital adrenal hyperplasia. J. Psychosom. Obst. Gynaec., 17: 175, 1996.
32. Stockholm abstract. Horm. Res., suppl., 48: 22, 1997.
33. Seckl, J. R. and Miller, W. L.: How safe is long-term prenatal glucocorticoid treatment? (Editorial). J.A.M.A., 277: 1077, 1997.
34. Pang, S., Clark, A. T., Freeman, L. C., Dolan, L. M., Immken, L., Mueller, O. T., Stiff, D. and Shulman, D. I.: Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J. Clin. Endocr. Metab., 75: 249, 1992.
35. Balsamo, A., Cacciari, E., Piazzi, S., Cassio, A., Bozza, D., Pirazzoli, P. and Zappulla, F.: Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics, 98: 362, 1996.
36. Cutfield, W. S., Webster, D.: Newborn screening for congenital adrenal hyperplasia in New Zealand. J. Ped., 126: 118, 1995.